Binder Gwendolyn 4
4 · Cabaletta Bio, Inc. · Filed Jan 19, 2024
Insider Transaction Report
Form 4
Binder Gwendolyn
President, Science & Tech.
Transactions
- Sale
Common Stock
2024-01-19$19.54/sh−10,300$201,211→ 20,700 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-19−11,000→ 100,756 totalExercise: $1.01Exp: 2028-10-28→ Common Stock (11,000 underlying) - Exercise/Conversion
Common Stock
2024-01-19$1.01/sh+11,000$11,110→ 31,000 total - Sale
Common Stock
2024-01-19$20.33/sh−700$14,229→ 20,000 total
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.16 - $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 - $20.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.